Nexavar
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Bayer’s liver cancer drug availability spreads to UK with NICE approval
August 10, 2017Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Mixed results for new leukaemia drugs
December 9, 2014Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib
Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …
US regulator shows Nexavar green light
November 25, 2013Sales and Marketing Bayer, Cancer, FDA, Nexavar, Onyx, thyroid
The FDA has extended the indication of liver and kidney cancer pill Nexavar to treat late-stage differentiated thyroid cancer. It …
Survival boost for Votrient in mRCC
October 2, 2012Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …
Bayer raises guidance after strong sales
July 31, 2012Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin
The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
FDA approves Pfizer cancer drug Inlyta
January 30, 2012Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma
Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …
Pfizer files new kidney cancer drug
June 2, 2011Sales and Marketing Nexavar, Pfizer, rcc
Pfizer has filed its kidney cancer drug axitinib in the EU after impressive head-head- trials with Bayer’s Nexavar. Pfizer is …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Pfizer’s axitinib impresses in head-to-head trial with Nexavar
November 22, 2010Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma
Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
Nexavar fails in lung cancer trial
June 15, 2010Research and Development Bayer, NSCLC, Nexavar, Onyx
Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
